Hospitals in Switzerland compete with one another for patients.
Review board’s new reference countries have more limited access to new and innovative drugs.
The original OHIP+ provided limited coverage to a population that largely didn’t need assistance.
U.S. pharmaceutical innovation has been disproportionately funded by U.S. consumers of patented drugs.
In Switzerland, the health-care system features managed competition among insurance companies and health-care providers.
In most countries with universal health care, patients share the cost of treatment—surgical or pharmaceutical.
Unlike Canadians, Germans do not face long wait times for health care.
Insurance companies are the principal beneficiaries of Ontario’s new publicly-funded pharmacare program.
In the Commonwealth Fund’s rankings of health-care systems, Canada scored a dismal ninth out of 11 countries.
Single-payer health-care systems are often only able to lower costs by rationing services.